Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Mulder

Showing results (131-140 of 147) with videos related to

Pageof 15
Sort By:
Scandinavian Journal of Gastroenterology|March 7, 1998
CD44 splice variants as prognostic markers in colorectal cancerV J Wielenga, R van der Voort, J W Mulder, et al.
Therapeutic Drug Monitoring|August 15, 2000
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavirP W Hugen, D M Burger, M de Graaff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2000
Nevirapine plus didanosine: once or twice daily combination?R P van Heeswijk, A I Veldkamp, J W Mulder, et al.
Journal of Viral Hepatitis|February 19, 2009
Comprehensive longitudinal analysis of hepatitis C virus (HCV)-specific T cell responses during acute HCV infection in the presence of existing HIV-1 infectionC H S B van den Berg, T A Ruys, N M Nanlohy, et al.
Journal of Clinical Microbiology|February 3, 2000
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patientsB S Blank, P L Meenhorst, J W Mulder, et al.
Journal of Clinical Pharmacy and Therapeutics|April 8, 2004
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-careM M R de Maat, A de Boer, C H W Koks, et al.
AIDS (London, England)|June 15, 2000
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individualsR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 27, 1999
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]M H Reijers, G J Weverling, S Jurriaans, et al.
HIV Medicine|March 12, 2004
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapyF van Leth, F W N M Wit, P Reiss, et al.
Pageof 15

Showing results (131-140 of 147) with videos related to

Sort By:
Pageof 15
Scandinavian Journal of Gastroenterology|March 7, 1998
CD44 splice variants as prognostic markers in colorectal cancerV J Wielenga, R van der Voort, J W Mulder, et al.
Therapeutic Drug Monitoring|August 15, 2000
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavirP W Hugen, D M Burger, M de Graaff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 7, 2000
Nevirapine plus didanosine: once or twice daily combination?R P van Heeswijk, A I Veldkamp, J W Mulder, et al.
Journal of Viral Hepatitis|February 19, 2009
Comprehensive longitudinal analysis of hepatitis C virus (HCV)-specific T cell responses during acute HCV infection in the presence of existing HIV-1 infectionC H S B van den Berg, T A Ruys, N M Nanlohy, et al.
Journal of Clinical Microbiology|February 3, 2000
Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patientsB S Blank, P L Meenhorst, J W Mulder, et al.
Journal of Clinical Pharmacy and Therapeutics|April 8, 2004
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-careM M R de Maat, A de Boer, C H W Koks, et al.
AIDS (London, England)|June 15, 2000
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individualsR P van Heeswijk, A I Veldkamp, J W Mulder, et al.
Lancet (London, England)|July 31, 1998
Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) studyM H Reijers, G J Weverling, S Jurriaans, et al.
Nederlands Tijdschrift Voor Geneeskunde|February 27, 1999
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]M H Reijers, G J Weverling, S Jurriaans, et al.
HIV Medicine|March 12, 2004
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapyF van Leth, F W N M Wit, P Reiss, et al.
Pageof 15